Vidcast:  https://www.instagram.com/p/C48pAtGLNIy/

The FDA has improved what is described as a new treatment for certain chronic nasal and sinus infections.

This therapy for so-called chronic rhinosinusitis without nasal polyps employs the long-used steroid nasal spray fluticasone, branded as Flonase, but delivers this drug using a novel dispenser that employs a higher pressure exhalation delivery system called the Xhance, marketed by the Opinose company.  The device sports a blow hole into which the patient forces air under pressure.  This pressurized exhaled air carries the steroid mist up into the higher reaches of the nasal cavity.  

Two company-sponsored so-called phase 3 studies demonstrated that the Xhance system with the topical steroid versus a comparable exhalation delivery system with placebo solution led to fewer nasal and sinus symptoms and improved sinus aeration on imaging.  It would seem that the controls are flawed.  An appropriate control would be the Xhance exhalation steroid delivery system vs a conventional aerosol steroid delivery system. That would show that the exhalation pressurization actually drives benefit.

Only time will tell if this system advances sinus therapy, but it may be worth a try if other therapy has failed you. 

https://www.xhance.com/using-xhance/#video

#rhinosinusitis #polyps #fluticasone #topical #steroids #xhance #Flonase